CN114403333A - Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof - Google Patents
Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof Download PDFInfo
- Publication number
- CN114403333A CN114403333A CN202210170102.2A CN202210170102A CN114403333A CN 114403333 A CN114403333 A CN 114403333A CN 202210170102 A CN202210170102 A CN 202210170102A CN 114403333 A CN114403333 A CN 114403333A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- effervescent tablet
- heatstroke
- fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 59
- 206010019345 Heat stroke Diseases 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 27
- 239000000284 extract Substances 0.000 claims abstract description 74
- 239000004088 foaming agent Substances 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims abstract description 48
- 230000002378 acidificating effect Effects 0.000 claims abstract description 46
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 44
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 44
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000000796 flavoring agent Substances 0.000 claims abstract description 36
- 239000000945 filler Substances 0.000 claims abstract description 35
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 35
- 239000000314 lubricant Substances 0.000 claims abstract description 27
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960003080 taurine Drugs 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 21
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 21
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 21
- 239000000853 adhesive Substances 0.000 claims abstract description 21
- 230000001070 adhesive effect Effects 0.000 claims abstract description 21
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 21
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 21
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 21
- 239000011718 vitamin C Substances 0.000 claims abstract description 21
- 239000001103 potassium chloride Substances 0.000 claims abstract description 20
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 20
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- 239000004475 Arginine Substances 0.000 claims abstract description 19
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 19
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 19
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 19
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 19
- 229960000367 inositol Drugs 0.000 claims abstract description 19
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241001165494 Rhodiola Species 0.000 claims abstract description 17
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 15
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 15
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 12
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 11
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 9
- 229960003121 arginine Drugs 0.000 claims abstract description 9
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 9
- 229960002743 glutamine Drugs 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 54
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 38
- 238000002156 mixing Methods 0.000 claims description 36
- 239000008187 granular material Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- 229930003270 Vitamin B Natural products 0.000 claims description 30
- 235000019156 vitamin B Nutrition 0.000 claims description 30
- 239000011720 vitamin B Substances 0.000 claims description 30
- 238000007873 sieving Methods 0.000 claims description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 229930091371 Fructose Natural products 0.000 claims description 20
- 239000005715 Fructose Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- 235000015165 citric acid Nutrition 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 16
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 15
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 15
- 244000298697 Actinidia deliciosa Species 0.000 claims description 15
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 15
- 244000144730 Amygdalus persica Species 0.000 claims description 15
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 15
- 240000002319 Citrus sinensis Species 0.000 claims description 15
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 15
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 15
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 15
- 229960004998 acesulfame potassium Drugs 0.000 claims description 15
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 15
- 239000000619 acesulfame-K Substances 0.000 claims description 15
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000001630 malic acid Substances 0.000 claims description 15
- 235000011090 malic acid Nutrition 0.000 claims description 15
- 239000000377 silicon dioxide Substances 0.000 claims description 15
- 235000012239 silicon dioxide Nutrition 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- 235000002906 tartaric acid Nutrition 0.000 claims description 15
- 239000011975 tartaric acid Substances 0.000 claims description 15
- 108010011485 Aspartame Proteins 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 13
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000000750 progressive effect Effects 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 7
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 17
- 235000001014 amino acid Nutrition 0.000 abstract description 10
- 150000001413 amino acids Chemical class 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 239000003792 electrolyte Substances 0.000 abstract description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 6
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 4
- 229930003451 Vitamin B1 Natural products 0.000 abstract description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract description 3
- 229960003495 thiamine Drugs 0.000 abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 3
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 3
- 229940011671 vitamin b6 Drugs 0.000 abstract description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 abstract description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 2
- 229930003471 Vitamin B2 Natural products 0.000 abstract description 2
- 229960002477 riboflavin Drugs 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 235000019164 vitamin B2 Nutrition 0.000 abstract description 2
- 229960002816 potassium chloride Drugs 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- 241000220223 Fragaria Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 235000013361 beverage Nutrition 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 244000042430 Rhodiola rosea Species 0.000 description 4
- 235000003713 Rhodiola rosea Nutrition 0.000 description 4
- 235000006533 astragalus Nutrition 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 210000004233 talus Anatomy 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- -1 Mg2+ ions Chemical class 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 201000007590 ariboflavinosis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000004223 riboflavin deficiency Diseases 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a heatstroke prevention and fatigue resistance effervescent tablet, which comprises astragalus extract, rhodiola extract, honeysuckle extract powder, schisandra extract powder, glutamine, arginine, aspartic acid, taurine, vitamin B1, vitamin B2, vitamin B6, vitamin C, nicotinamide, inositol, sodium chloride, potassium chloride, an acidic foaming agent, an alkaline foaming agent, a filling agent, an adhesive, a lubricant and a flavoring agent; the effervescent tablet has the functions of preventing heatstroke and resisting fatigue, selects raw materials for preventing heatstroke and relieving body fatigue from various traditional Chinese medicine components, amino acids, vitamins and electrolytes, is scientifically proportioned, and can be used for rapidly supplementing energy and electrolytes in a targeted manner to fatigue and electrolyte imbalance caused by work and life in high-temperature weather, so that heatstroke and fatigue can be effectively prevented and relieved.
Description
Technical Field
The invention relates to a health-care beverage, in particular to a heatstroke-preventing and fatigue-resisting effervescent tablet and a preparation method thereof.
Background
The effervescent tablet is a novel solid preparation, the effervescent tablet is a tablet containing effervescent disintegrant, two substances in the effervescent disintegrant are not ionized and can not react, but after the effervescent tablet is placed into water, the two substances generate acid-base reaction to generate a large amount of bubbles (carbon dioxide) so that the tablet is rapidly disintegrated, and the bubbles generated by disintegration can also enable the tablet to roll up and down in the water to accelerate the disintegration of the tablet. The carbon dioxide generated when the tablet disintegrates is partially dissolved in the drinking water, so that the drinking water has the aesthetic feeling like soda water when being drunk in the mouth. The effervescent tablet has the advantages of rapid disintegration, convenient administration, rapid action, high bioavailability, and improved clinical effect. However, the existing effervescent tablets have single function and weak functionality, and particularly cannot simultaneously have the functions of heatstroke prevention and fatigue resistance.
Disclosure of Invention
In view of the above, the present invention aims to provide a heatstroke preventing and fatigue resisting effervescent tablet and a preparation method thereof, and the effervescent tablet has heatstroke preventing and fatigue resisting functions.
The invention relates to a heatstroke prevention and fatigue resistance effervescent tablet, which comprises the following raw materials in parts by weight: 1-5 parts of astragalus extract, 1-5 parts of rhodiola extract, 1-5 parts of honeysuckle extract powder, 1-5 parts of schisandra extract powder, 1-5 parts of glutamine, 1-5 parts of arginine, 1-5 parts of aspartic acid, 1-5 parts of taurine, 10.01-0.1 part of vitamin B, 20.01-0.1 part of vitamin B, 60.01-0.1 part of vitamin B, 0.5-2 parts of vitamin C, 0.1-2 parts of nicotinamide, 0.5-2 parts of inositol, 0.5-10 parts of sodium chloride, 0.1-5 parts of potassium chloride, 10-30 parts of acidic foaming agent, 10-30 parts of alkaline foaming agent, 20-60 parts of filler, 1-5 parts of adhesive, 2-10 parts of lubricant and 2-10 parts of flavoring agent;
further, the effervescent tablet comprises the following raw materials in parts by weight: 3 parts of astragalus extract, 3 parts of rhodiola extract, 3 parts of honeysuckle extract powder, 3 parts of schisandra extract powder, 3 parts of glutamine, 3 parts of arginine, 3 parts of aspartic acid, 3 parts of taurine, 10.05 parts of vitamin B, 20.05 parts of vitamin B, 60.05 parts of vitamin B, 1.2 parts of vitamin C, 0.6 part of nicotinamide, 1.2 parts of inositol, 5 parts of sodium chloride, 2.5 parts of potassium chloride, 20 parts of acidic foaming agent, 20 parts of alkaline foaming agent, 40 parts of filler, 3 parts of adhesive, 6 parts of lubricant and 6 parts of flavoring agent;
further, the acidic foaming agent is one or a mixture of more than two of citric acid, tartaric acid and malic acid;
further, the alkaline foaming agent is one or two of sodium carbonate and sodium bicarbonate;
further, the filler is one or a mixture of more than two of glucose, fructose, sucrose, lactose, acesulfame potassium and aspartame;
further, the adhesive is one or two of polyvinylpyrrolidone-K30 and absolute ethyl alcohol; further, the lubricant is one or a mixture of more than two of magnesium stearate, silicon dioxide and polyethylene glycol 6000, and the flavoring agent is one or a mixture of more than two of artificial essence, sweet orange essence, strawberry essence, honey peach essence and kiwi essence.
The preparation method of the heatstroke prevention and fatigue resistance effervescent tablet comprises the following steps:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 60-70 deg.C for 1-2 hr, and sieving to obtain acidic granule;
c. uniformly mixing the acidic granules, the alkaline granules and the flavoring agent according to a method of adding the acidic granules, the alkaline granules and the flavoring agent in a progressive manner in proportion, and tabletting to obtain an effervescent tablet preparation;
further, in the step b, the honeysuckle extract powder is prepared by the following steps: pulverizing dried flos Lonicerae, sieving, extracting with 95% (V/V) ethanol under continuous reflux, filtering the extractive solution, concentrating under reduced pressure to constant weight to obtain flos Lonicerae extract, mixing with adjuvants, and spray drying to obtain flos Lonicerae extract powder;
further, in the step b, the schisandra chinensis extract powder is prepared by the following steps: drying fructus Schisandrae, pulverizing, sieving, extracting with 95% (V/V) ethanol under reflux, filtering, concentrating under reduced pressure to constant weight to obtain fructus Schisandrae extract, mixing with adjuvants, and spray drying to obtain fructus Schisandrae extract powder.
The invention has the beneficial effects that: the effervescent tablet has the functions of preventing heatstroke and resisting fatigue, selects raw materials for preventing heatstroke and relieving body fatigue from various traditional Chinese medicine components, amino acid, vitamins and electrolyte, is scientifically proportioned, and can be used for rapidly supplementing energy and electrolyte in a targeted manner to fatigue and electrolyte imbalance caused by work and life in high-temperature weather, so that heatstroke and fatigue can be effectively prevented and relieved. In addition, the preparation process of acidic granulation and alkaline granulation is respectively carried out by combining the technical means of pharmaceutic preparation, and the preparation method has the characteristics of easy storage, good stability, good solubility, increased interest in gas generation in the dissolving process and the like.
The radix astragali extract contains effective bioactive components of radix astragali, astragalus polysaccharides and astragaloside IV. Wherein, the astragaloside IV is called as super astragalus polysaccharide, the drug effect strength is more than 2 times of that of the conventional astragalus polysaccharide, and the antiviral effect is more than 30 times of that of the astragalus polysaccharide. The astragalus extract has prominent functions of enhancing the immunity of organisms and improving the immune defense function, and mainly has the function of resisting viruses by promoting the activation of immune cells to release endogenous factors. The astragalus extract has obvious effect of regulating the metabolic process of nutrient substances, simultaneously promotes the growth of bifidobacterium and lactobacillus, relieves and eliminates the influence of thermal environment on the physiological function of gastrointestinal tract of an organism to a certain extent, and has the functions of stress resistance, nutrition and health care. In addition, the radix astragali extract has effects of improving cardiopulmonary function, protecting liver, and resisting inflammation.
The rhodiola rosea extract contains the effective active ingredients of rhodiola rosea and salidroside. The preparation is used for health protection of workers in sports medicine, aerospace medicine and various special environmental conditions. The radix Rhodiolae has effects of adapting original shape and regulating bidirectionally, and can improve organism adaptability in anoxia environment and thermal environment, protect cardiovascular function, and shorten recovery time of muscle fatigue.
Honeysuckle extract powder, honeysuckle is known as a good medicine for clearing heat and removing toxicity from old times. It is sweet and cold in nature and fragrant in nature, and sweet and cold in nature and clearing heat without damaging the stomach. It can disperse wind-heat and clear blood toxin, and can be used for treating various febrile diseases. It is combined with Huang Qi to tonify qi, remove toxicity and activate blood.
The schisandra extract powder and schisandra sexual acid have the effects of promoting the production of body fluid and quenching thirst and have the treatment effect on spontaneous perspiration and night sweat. The Tang Dynasty Wang Sun Si far away is written in Qian jin Fang: wuyue is usually eaten to nourish five zang organs. When it meets the middle of summer, it is tired and weak without moving air, and it is decocted with Huangbai to make people feel vigorous and have two feet.
Glutamine is the most abundant free amino acid in muscle, accounts for about 60 percent of the total amount of the free amino acid of a human body, provides a necessary nitrogen source for an organism and promotes the synthesis of protein in muscle cells; the growth and differentiation of muscle cells are promoted by the cell compatibilization effect. During exercise, the increase in body acid metabolites acidifies body fluids. Glutamine has the potential to generate bases, thereby reducing the decrease in exercise capacity or fatigue caused by acidic substances to some extent. Therefore, under the conditions of high-intensity sports, labor and the like, the demand of the body for glutamine increases, so that self-synthesis cannot meet the demand. Both animal and human experimental studies have revealed that glutamine supplementation can increase body strength and improve endurance. The glutamine is supplemented, the oxidation resistance of the organism can be improved by keeping and increasing the storage of glutathione in tissue cells, cell membranes and protein structures are stabilized, the functions of important organs such as liver, lung, intestinal tract and the like and immunocytes are protected, and the normal functions of kidney, pancreas, gall bladder and liver are maintained.
Aspartic acid can be used as carrier of K + and Mg2+ ions to deliver electrolyte to myocardium, thereby improving myocardial contraction function, reducing oxygen consumption, and protecting myocardium. It participates in ornithine circulation, promotes ammonia and carbon dioxide to produce urea, reduces the amount of nitrogen and carbon dioxide in blood, enhances liver function, and eliminates fatigue. Aspartic acid is also a good nutritional supplement, is matched with various amino acids, and can be used as a fatigue recovery agent.
Taurine can relieve lipid peroxidation caused by exercise, promote the increase of antioxidant enzyme activity of an organism after exercise, protect cells from function reduction caused by exercise, and further delay the occurrence of exercise-induced fatigue. Taurine is a sulfur-containing amino acid in animals, but is not a constituent of proteins, and is widely distributed in various organ tissues of human and animals, especially heart, in the form of free amino acid, and accounts for as much as 50% of the total amount of free amino acid. Research shows that taurine can promote pituitary hormone secretion, activate pancreatic gland function, improve the state of secretion system in organism and enhance immunity and antifatigue effect of organism.
Water-soluble vitamins B1, B2, B6, niacinamide and vitamin C are widely involved in various physiological processes as coenzymes or prosthetic groups. Animals and some microorganisms cannot synthesize the vitamin, so the vitamin is required to be obtained from the outside, and the demand of the body for the vitamin is not high but is indispensable. Vitamin B1 is a coenzyme of decarboxylase and dehydrogenase in sugar metabolism, and is mainly used for maintaining normal sugar metabolism, stimulating appetite and maintaining normal nervous activity. When vitamin B1 is not ingested, mild patients will be manifested as muscular weakness, apathy and anorexia, and severe patients will have beriberi. Vitamin B2 participates in the redox reaction and energy generation in vivo, also participates in the antioxidant defense system in vivo, and improves the adaptive capacity of organism to environmental stress. Vitamin B2 deficiency can lead to substance metabolism disorder and influence iron absorption, is prone to secondary iron deficiency anemia, and also influences metabolism of vitamin B6 and nicotinic acid. Vitamin B6 is a coenzyme of many enzyme systems in the body, and is involved in decarboxylation of amino acids, transamination, synthesis of tryptophan, metabolism of sulfur-containing amino acids, formation of aminolevulinic acid, metabolism of unsaturated fatty acids, and the like. Nicotinamide is a component of both coenzyme I and coenzyme II, which is a coenzyme for many dehydrogenases. Vitamin C, also known as ascorbic acid, participates in hydroxylation reaction, can be used as a hydrogen donor and a hydrogen acceptor, plays an important role in the in-vivo redox process, and is an important auxiliary medicine for treating anemia.
Glucose and fructose have both bulking and energy supplements. Glucose is an energy source and metabolic intermediate product of living cells, and is a main energy supply substance. The fructose has fruity flavor and high sweetness, and is not easy to cause dental caries. It has been found that if equal amounts of fructose and glucose are ingested, the rate of oxidation is 21% higher than if 100 g of glucose is ingested alone. Fructose and glucose are less competitive with each other because of their different oxidation pathways, and thus intake of fructose during exercise is also beneficial.
Sodium chloride and potassium chloride are involved in many important functions and metabolic activities in the body as electrolytes, and play a very important role in the maintenance of normal vital activities. In normal human bodies, sodium ions account for 92% of the total amount of cations in extracellular fluid, and potassium ions account for about 98% of the total amount of cations in intracellular fluid. After a large amount of sweating, the imbalance of sodium and potassium ions can cause corresponding obstacles to the physiological functions of all organ systems of the whole body, especially the cardiovascular system and the nervous system and the metabolism of the substances of the body.
Detailed Description
The following examples are provided to further illustrate the present invention for better understanding, but the present invention is not limited to the following examples.
In the examples, the experimental methods used were all conventional methods unless otherwise specified, and the materials, reagents and the like used were commercially available without otherwise specified.
Example one
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 1 part of astragalus extract, 1 part of rhodiola extract, 1 part of honeysuckle extract powder, 1 part of schisandra extract powder, 1 part of glutamine, 1 part of arginine, 1 part of aspartic acid, 1 part of taurine, 10.01 parts of vitamin B, 20.01 parts of vitamin B, 60.01 parts of vitamin B, 0.5 part of vitamin C, 0.1 part of nicotinamide, 0.5 part of inositol, 0.5 part of sodium chloride, 0.1 part of potassium chloride, 10 parts of acidic foaming agent, 10 parts of alkaline foaming agent, 20 parts of filler, 1 part of adhesive, 2 parts of lubricant and 2 parts of flavoring agent.
In the embodiment, the acidic foaming agent is citric acid, and in the embodiment, the citric acid is replaced by one of tartaric acid and malic acid or a mixture of citric acid, tartaric acid and malic acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium carbonate or sodium bicarbonate.
In the embodiment, the filler is glucose, and in the embodiment, glucose is replaced by one of fructose, sucrose, lactose, acesulfame potassium and aspartame or a mixture of glucose, fructose, sucrose, lactose, acesulfame potassium and aspartame according to the same weight part, so that qualified products are obtained.
In this embodiment, the binder is polyvinylpyrrolidone-K30 or absolute ethanol.
In the embodiment, the lubricant is magnesium stearate, and in the embodiment, the magnesium stearate is replaced by one of silicon dioxide and polyethylene glycol 6000 or replaced by a mixture of magnesium stearate, silicon dioxide and polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is artificial essence, and in the embodiment, the artificial essence is replaced by one of sweet orange essence, strawberry essence, juicy peach essence and kiwi fruit essence or a mixture of the artificial essence, the sweet orange essence, the strawberry essence, the juicy peach essence and the kiwi fruit essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 60 deg.C for 1 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
Example two
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 5 parts of astragalus extract, 5 parts of rhodiola rosea extract, 5 parts of honeysuckle extract powder, 5 parts of schisandra extract powder, 5 parts of glutamine, 5 parts of arginine, 5 parts of aspartic acid, 5 parts of taurine, 10.1 parts of vitamin B, 20.1 parts of vitamin B, 60.1 parts of vitamin B, 2 parts of vitamin C, 2 parts of nicotinamide, 2 parts of inositol, 10 parts of sodium chloride, 5 parts of potassium chloride, 30 parts of acidic foaming agent, 30 parts of alkaline foaming agent, 60 parts of filler, 5 parts of adhesive, 10 parts of lubricant and 10 parts of flavoring agent.
In the embodiment, the acidic foaming agent is tartaric acid, and in the embodiment, the tartaric acid is replaced by one of citric acid and malic acid or replaced by a mixture of tartaric acid, citric acid and malic acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium carbonate.
In the embodiment, the filler is fructose, and in the embodiment, the fructose is replaced by one of glucose, sucrose, lactose, acesulfame potassium and aspartame or a mixture of fructose, glucose, sucrose, lactose, acesulfame potassium and aspartame according to the same weight part, so that qualified products are obtained.
In this embodiment, the binder is absolute ethyl alcohol.
In the embodiment, the lubricant is magnesium stearate, and in the embodiment, the magnesium stearate is replaced by one of silicon dioxide and polyethylene glycol 6000 or replaced by a mixture of magnesium stearate, silicon dioxide and polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is sweet orange essence, and in the embodiment, the sweet orange essence is replaced by one of artificial essence, strawberry essence, juicy peach essence and kiwi fruit essence or a mixture of the sweet orange essence, the artificial essence, the strawberry essence, the juicy peach essence and the kiwi fruit essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 70 deg.C for 2 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
EXAMPLE III
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 1 part of astragalus extract, 5 parts of rhodiola rosea extract, 1 part of honeysuckle extract powder, 5 parts of schisandra extract powder, 1 part of glutamine, 5 parts of arginine, 1 part of aspartic acid, 5 parts of taurine, 10.01 parts of vitamin B, 20.1 parts of vitamin B, 60.01 parts of vitamin B, 2 parts of vitamin C, 0.1 part of nicotinamide, 2 parts of inositol, 0.5 part of sodium chloride, 5 parts of potassium chloride, 10 parts of acidic foaming agent, 30 parts of alkaline foaming agent, 20 parts of filler, 5 parts of adhesive, 2 parts of lubricant and 10 parts of flavoring agent.
In the embodiment, the acidic foaming agent is malic acid, and in the embodiment, the malic acid is replaced by one of tartaric acid and citric acid or replaced by a mixture of malic acid, tartaric acid and citric acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium bicarbonate.
In the embodiment, the filler is sucrose, and in the embodiment, the sucrose is replaced by one of fructose, glucose, lactose, acesulfame potassium and aspartame or a mixture of sucrose, fructose, glucose, lactose, acesulfame potassium and aspartame according to the same weight part, so that qualified products are obtained.
In this example, the binder is polyvinylpyrrolidone-K30 and absolute ethanol.
In the embodiment, the lubricant is silicon dioxide, and in the embodiment, the silicon dioxide is replaced by one of magnesium stearate and polyethylene glycol 6000 or replaced by a mixture of the silicon dioxide, the magnesium stearate and the polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is strawberry essence, and in the embodiment, the strawberry essence is replaced by one of sweet orange essence, artificial essence, juicy peach essence and kiwi fruit essence or a mixture of the strawberry essence, the sweet orange essence, the artificial essence, the juicy peach essence and the kiwi fruit essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 65 deg.C for 1.5 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
Example four
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 5 parts of astragalus extract, 1 part of rhodiola extract, 5 parts of honeysuckle extract powder, 1 part of schisandra extract powder, 5 parts of glutamine, 1 part of arginine, 5 parts of aspartic acid, 1 part of taurine, 10.1 parts of vitamin B, 20.01 parts of vitamin B, 60.1 parts of vitamin B, 0.5 part of vitamin C, 2 parts of nicotinamide, 0.5 part of inositol, 10 parts of sodium chloride, 0.1 part of potassium chloride, 30 parts of acidic foaming agent, 10 parts of alkaline foaming agent, 60 parts of filler, 1 part of adhesive, 10 parts of lubricant and 2 parts of flavoring agent.
In the embodiment, the acidic foaming agent is citric acid, and in the embodiment, the citric acid is replaced by one of tartaric acid and malic acid or a mixture of citric acid, tartaric acid and malic acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium carbonate and sodium bicarbonate.
In the embodiment, the filler is lactose, and in the embodiment, lactose is replaced by one of fructose, sucrose, glucose, acesulfame potassium and aspartame or a mixture of lactose, fructose, sucrose, glucose, acesulfame potassium and aspartame according to the same weight part, so that qualified products are obtained.
In this example, the binder is polyvinylpyrrolidone-K30 and absolute ethanol.
In the embodiment, the lubricant is magnesium stearate, and in the embodiment, the magnesium stearate is replaced by one of silicon dioxide and polyethylene glycol 6000 or replaced by a mixture of magnesium stearate, silicon dioxide and polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is honey peach essence, and in the embodiment, the honey peach essence is replaced by one of sweet orange essence, strawberry essence, artificial essence and kiwi fruit essence or a mixture of the honey peach essence, the sweet orange essence, the strawberry essence, the artificial essence and the kiwi fruit essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 664 deg.C for 1 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
EXAMPLE five
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 2 parts of astragalus extract, 4 parts of rhodiola extract, 3 parts of honeysuckle extract powder, 1 part of schisandra extract powder, 4 parts of glutamine, 1 part of arginine, 5 parts of aspartic acid, 3 parts of taurine, 10.01 parts of vitamin B, 20.07 parts of vitamin B, 60.01 parts of vitamin B, 2 parts of vitamin C, 0.8 part of nicotinamide, 1.5 parts of inositol, 3 parts of sodium chloride, 4 parts of potassium chloride, 15 parts of acidic foaming agent, 20 parts of alkaline foaming agent, 50 parts of filler, 1 part of adhesive, 8 parts of lubricant and 6 parts of flavoring agent.
In the embodiment, the acidic foaming agent is citric acid, and in the embodiment, the citric acid is replaced by one of tartaric acid and malic acid or a mixture of citric acid, tartaric acid and malic acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium carbonate.
In the embodiment, the filler is acesulfame potassium, and the acesulfame potassium is replaced by one of fructose, sucrose, lactose, glucose and aspartame or a mixture of acesulfame potassium and fructose, sucrose, lactose, glucose and aspartame according to the same weight part, so that qualified products are obtained.
In this example, the binder is polyvinylpyrrolidone-K30.
In the embodiment, the lubricant is magnesium stearate, and in the embodiment, the magnesium stearate is replaced by one of silicon dioxide and polyethylene glycol 6000 or replaced by a mixture of magnesium stearate, silicon dioxide and polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is kiwi fruit essence, and in the embodiment, the kiwi fruit essence is replaced by one of sweet orange essence, strawberry essence, honey peach essence and artificial essence or a mixture of the kiwi fruit essence, the sweet orange essence, the strawberry essence, the honey peach essence and the artificial essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 65 deg.C for 1.5 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
EXAMPLE six
The heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following raw materials in parts by weight: 3 parts of astragalus extract, 3 parts of rhodiola extract, 3 parts of honeysuckle extract powder, 3 parts of schisandra extract powder, 3 parts of glutamine, 3 parts of arginine, 3 parts of aspartic acid, 3 parts of taurine, 10.05 parts of vitamin B, 20.05 parts of vitamin B, 60.05 parts of vitamin B, 1.2 parts of vitamin C, 0.6 part of nicotinamide, 1.2 parts of inositol, 5 parts of sodium chloride, 2.5 parts of potassium chloride, 20 parts of acidic foaming agent, 20 parts of alkaline foaming agent, 40 parts of filler, 3 parts of adhesive, 6 parts of lubricant and 6 parts of flavoring agent.
In the embodiment, the acidic foaming agent is citric acid, and in the embodiment, the citric acid is replaced by one of tartaric acid and malic acid or a mixture of citric acid, tartaric acid and malic acid according to the same weight part, so that qualified products are obtained.
In this embodiment, the alkaline foaming agent is sodium bicarbonate.
In the embodiment, the filler is glucose, and in the embodiment, glucose is replaced by one of fructose, sucrose, lactose, acesulfame potassium and aspartame or a mixture of glucose, fructose, sucrose, lactose, acesulfame potassium and aspartame according to the same weight part, so that qualified products are obtained.
In this embodiment, the binder is polyvinylpyrrolidone-K30 or absolute ethanol.
In the embodiment, the lubricant is magnesium stearate, and in the embodiment, the magnesium stearate is replaced by one of silicon dioxide and polyethylene glycol 6000 or replaced by a mixture of magnesium stearate, silicon dioxide and polyethylene glycol 6000 according to the same weight parts, so that qualified products are obtained.
In the embodiment, the flavoring agent is artificial essence, and in the embodiment, the artificial essence is replaced by one of sweet orange essence, strawberry essence, juicy peach essence and kiwi fruit essence or a mixture of the artificial essence, the sweet orange essence, the strawberry essence, the juicy peach essence and the kiwi fruit essence according to the same weight part, so that qualified products are obtained.
The preparation method of the heatstroke-preventing and fatigue-resisting effervescent tablet comprises the following steps of:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 65 deg.C for 1.2 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
The heatstroke prevention and fatigue resistance effervescent tablet of the first embodiment is used for animal experiments:
(1) 40C 57BL/6 mice were taken and randomly divided into a control group, a low dose group, a medium dose group and a high dose group, each of which was 10 mice. The control group was given distilled water as daily drinking water. The low dose group, the medium dose group and the high dose group were prepared by replacing the daily drinking water of mice with the effervescent tablet beverage of the present invention at different concentrations. The diet was the same. After drinking for 30d, the change in body weight was recorded. The experimental result judges the difference significance among the groups according to the p < 0.05.
(2) Weight swimming time measurement
When the mouse is subjected to the experiment of exhaustion of swimming under load, an iron wire which is 5.5 percent of the weight of the mouse is added at the root of the tail in a position of 1cm, so that the mouse can freely move to exhaustion in a water tank with the depth of 50cm and the temperature of (25.5 +/-0.5) DEG C, and the time is counted.
(3) After the mouse is anesthetized by injecting 50mg/kg sodium pentobarbital into the abdominal cavity, blood is collected from an orbit, the blood is centrifuged for 30 minutes at the temperature of 4 ℃ at 3000 rpm, and serum is collected, subpackaged and stored at the temperature of minus 80 ℃ and used for detecting the biochemical indexes of the serum. The content of serum lactic acid, the activity of liver superoxide dismutase, the content of liver malondialdehyde and glutathione are measured by a kit; blood sugar, serum urea nitrogen and serum lactate dehydrogenase are detected by a full-automatic biochemical analyzer.
(4) C57BL/6 mice 24 were taken for heat resistance experiments. Before the mice enter the cabin, the diet and drinking water are stopped, all the mice are put into an intelligent simulation experiment cabin (Chinese Tianjin Hepu, HOPE-MED8105E type) with specific environment, the temperature (41.2 +/-0.5) DEG C and the humidity (60 +/-0.2)%, and the condition of getting out of the cabin according with the heatstroke standard is that the temperature of the anus of the mice reaches (42.4 +/-0.2) ° C. And continuously monitoring the anal temperature of the mice, taking out of the capsule when the anal temperature reaches 42.4 +/-0.2 ℃, and recording the capsule taking-out time and the weight.
TABLE 1 Effect of effervescent tablet beverages of the present invention on body weight in mice
| Group of | Dosage (g/L) | Initial body weight (g) | Final body weight (g) | Weight gain (g) |
| Control group | 0.0 | 24.0±1.8 | 31.4±1.3 | 7.5±0.8 |
| Low dose group | 5.0 | 23.8±1.2 | 31.5±1.7 | 7.7±0.6 |
| Middle dose group | 10.0 | 23.6±1.5 | 31.8±1.1 | 8.1±0.6* |
| High dose group | 15.0 | 23.9±1.3 | 31.7±1.1 | 7.8±0.5 |
Note indicates p < 0.05 compared to the blank control group; p < 0.01, compared to the blank control group.
TABLE 2 Effect of effervescent tablet beverages of the present invention on weight bearing swimming time of mice
| Group of | Dosage (g/L) | Swimming time(s) | P value |
| Control group | 0.0 | 225.80±33.64 | — |
| Low dose group | 5.0 | 257.07±41.80 | 0.247 |
| Middle dose group | 10.0 | 285.90±27.55** | 0.004 |
| High dose group | 15.0 | 284.30±42.46** | 0.006 |
Note indicates p < 0.05 compared to the blank control group; p < 0.01, compared to the blank control group.
TABLE 3 Effect of effervescent tablet beverages of the present invention on Biochemical indicators of mouse serum
Note indicates p < 0.05 compared to the blank control group; p < 0.01, compared to the blank control group.
TABLE 4 Effect of effervescent tablet beverages of the present invention on mouse liver antioxidant capacity
Note indicates p < 0.05 compared to the blank control group; p < 0.01 in comparison to the blank control group
TABLE 5 Effect of effervescent tablet beverages of the present invention on the Heat tolerance of mice
Note indicates p < 0.05 compared to the blank control group; p < 0.01 in comparison to the blank control group
And (4) conclusion: according to the effervescent tablet beverage, the average daily intake concentration of 10g/L is respectively set into three concentration dose groups, namely 5g/L of a low dose group, 10g/L of a medium dose group and 15g/L of a high dose group, and meanwhile, distilled water is given to a control group. SPF grade C57BL/6 mice were given the same diet and were given different concentrations of effervescent tablet beverage of the present invention for 30 consecutive days instead of daily drinking water for the mice. The results show that:
(1) there was no significant difference in body weight of mice in each group compared to the control group.
(2) Compared with the control group, the medium-dose group and the high-dose group have the effect of remarkably prolonging the weight swimming time of the mice.
(3) The serum biochemical indexes of the mice, namely the concentrations of urea nitrogen and lactic acid show that the medium-dose group and the high-dose group are obviously lower than those of a control group; and both blood glucose and lactate dehydrogenase showed significantly higher levels in the medium and high dose groups than in the control group.
(4) The concentrations of superoxide dismutase and glutathione were increased in both the medium dose group and the high dose group, and were significantly different from the control group.
(5) With the increase of the concentration of the effervescent tablet beverage, the heat-resistant time of the mouse under the same thermal environment is obviously prolonged.
The effervescent tablet beverage has the functions of preventing heatstroke and resisting fatigue according to the judgment of various test results.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (10)
1. An effervescent tablet for preventing heatstroke and resisting fatigue is characterized in that: the effervescent tablet comprises the following raw materials in parts by weight: 1-5 parts of astragalus extract, 1-5 parts of rhodiola extract, 1-5 parts of honeysuckle extract powder, 1-5 parts of schisandra extract powder, 1-5 parts of glutamine, 1-5 parts of arginine, 1-5 parts of aspartic acid, 1-5 parts of taurine, 10.01-0.1 part of vitamin B, 20.01-0.1 part of vitamin B, 60.01-0.1 part of vitamin B, 0.5-2 parts of vitamin C, 0.1-2 parts of nicotinamide, 0.5-2 parts of inositol, 0.5-10 parts of sodium chloride, 0.1-5 parts of potassium chloride, 10-30 parts of acidic foaming agent, 10-30 parts of alkaline foaming agent, 20-60 parts of filler, 1-5 parts of adhesive, 2-10 parts of lubricant and 2-10 parts of flavoring agent.
2. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 1, is characterized in that: the effervescent tablet comprises the following raw materials in parts by weight: 3 parts of astragalus extract, 3 parts of rhodiola extract, 3 parts of honeysuckle extract powder, 3 parts of schisandra extract powder, 3 parts of glutamine, 3 parts of arginine, 3 parts of aspartic acid, 3 parts of taurine, 10.05 parts of vitamin B, 20.05 parts of vitamin B, 60.05 parts of vitamin B, 1.2 parts of vitamin C, 0.6 part of nicotinamide, 1.2 parts of inositol, 5 parts of sodium chloride, 2.5 parts of potassium chloride, 20 parts of acidic foaming agent, 20 parts of alkaline foaming agent, 40 parts of filler, 3 parts of adhesive, 6 parts of lubricant and 6 parts of flavoring agent.
3. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 2, is characterized in that: the acidic foaming agent is one or a mixture of more than two of citric acid, tartaric acid and malic acid.
4. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 3, is characterized in that: the alkaline foaming agent is one or two of sodium carbonate and sodium bicarbonate.
5. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 4, is characterized in that: the filler is one or more of glucose, fructose, sucrose, lactose, acesulfame potassium and aspartame.
6. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 5, is characterized in that: the adhesive is one or two of polyvinylpyrrolidone-K30 and absolute ethyl alcohol.
7. The heatstroke-preventing fatigue-resisting effervescent tablet according to claim 6, is characterized in that: the lubricant is one or a mixture of more than two of magnesium stearate, silicon dioxide and polyethylene glycol 6000, and the flavoring agent is one or a mixture of more than two of artificial essence, sweet orange essence, strawberry essence, honey peach essence and kiwi essence.
8. The preparation method of the heatstroke prevention and fatigue resistance effervescent tablet according to claim 1, characterized in that: the method comprises the following steps:
a. heating the lubricant to a molten state, adding the astragalus extract, the rhodiola extract, the alkali foaming agent, the nicotinamide, the sodium chloride, the potassium chloride and the filler, stirring and mixing uniformly, cooling, crushing and sieving to obtain alkaline granules;
b. mixing flos Lonicerae extract powder, fructus Schisandrae extract powder, glutamine, arginine, aspartic acid, taurine, and vitamin B1Vitamin B2Vitamin B6Mixing vitamin C, inositol, acidic foaming agent, and filler uniformly, adding adhesive, granulating, sieving, drying at 60-70 deg.C for 1-2 hr, and sieving to obtain acidic granule;
c. and uniformly mixing the acidic granules, the alkaline granules and the flavoring agent by a method of adding the flavoring agent in a progressive manner according to a certain proportion, and tabletting to obtain the effervescent tablet preparation.
9. The preparation method of the effervescent tablet for preventing heatstroke and resisting fatigue according to claim 8 is characterized in that: in the step b, the honeysuckle extract powder is prepared by the following steps: pulverizing dried flos Lonicerae, sieving, extracting with 95% (V/V) ethanol under continuous reflux, filtering the extractive solution, concentrating under reduced pressure to constant weight to obtain flos Lonicerae extract, mixing with adjuvants, and spray drying to obtain flos Lonicerae extract powder.
10. The preparation method of the effervescent tablet for preventing heatstroke and resisting fatigue according to claim 9, characterized in that: in the step b, the schisandra chinensis extract powder is prepared by the following steps: drying fructus Schisandrae, pulverizing, sieving, extracting with 95% ethanol under reflux, filtering, concentrating under reduced pressure to constant weight to obtain fructus Schisandrae extract, mixing with adjuvants, and spray drying to obtain fructus Schisandrae extract powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210170102.2A CN114403333A (en) | 2022-02-23 | 2022-02-23 | Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210170102.2A CN114403333A (en) | 2022-02-23 | 2022-02-23 | Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114403333A true CN114403333A (en) | 2022-04-29 |
Family
ID=81261934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210170102.2A Pending CN114403333A (en) | 2022-02-23 | 2022-02-23 | Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114403333A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116076644A (en) * | 2023-03-16 | 2023-05-09 | 中国人民解放军陆军军医大学 | Solid beverage with protection function on organism cardiovascular in high temperature environment |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909916A (en) * | 2004-01-16 | 2007-02-07 | 亚美利技术股份有限公司 | Effervescent composition including cranberry extract |
| CN1994355A (en) * | 2006-12-28 | 2007-07-11 | 天津市天骄制药有限公司 | Gadol effervescence tablet |
| CN101181340A (en) * | 2007-11-28 | 2008-05-21 | 南京海陵中药制药工艺技术研究有限公司 | Astragalus essence effervescent tablets and preparation method thereof |
| CN102389116A (en) * | 2011-11-23 | 2012-03-28 | 武汉工程大学 | Effervescent tablet for alleviating physical fatigue and preparation technology thereof |
| CN110051717A (en) * | 2019-05-25 | 2019-07-26 | 广东大鹏医药科技有限公司 | A kind of honeysuckle VC effervescent tablet and preparation method thereof |
| CN113616608A (en) * | 2021-09-09 | 2021-11-09 | 长春工业大学 | Schisandra chinensis-VC composite effervescent tablet and preparation method thereof |
-
2022
- 2022-02-23 CN CN202210170102.2A patent/CN114403333A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909916A (en) * | 2004-01-16 | 2007-02-07 | 亚美利技术股份有限公司 | Effervescent composition including cranberry extract |
| CN1994355A (en) * | 2006-12-28 | 2007-07-11 | 天津市天骄制药有限公司 | Gadol effervescence tablet |
| CN101181340A (en) * | 2007-11-28 | 2008-05-21 | 南京海陵中药制药工艺技术研究有限公司 | Astragalus essence effervescent tablets and preparation method thereof |
| CN102389116A (en) * | 2011-11-23 | 2012-03-28 | 武汉工程大学 | Effervescent tablet for alleviating physical fatigue and preparation technology thereof |
| CN110051717A (en) * | 2019-05-25 | 2019-07-26 | 广东大鹏医药科技有限公司 | A kind of honeysuckle VC effervescent tablet and preparation method thereof |
| CN113616608A (en) * | 2021-09-09 | 2021-11-09 | 长春工业大学 | Schisandra chinensis-VC composite effervescent tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116076644A (en) * | 2023-03-16 | 2023-05-09 | 中国人民解放军陆军军医大学 | Solid beverage with protection function on organism cardiovascular in high temperature environment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI478709B (en) | A useful oral or enteral composition for the recovery of bodily functions | |
| CN102389116B (en) | Effervescent tablet for alleviating physical fatigue and preparation technology thereof | |
| CN100502692C (en) | Physical recovery healthy food and preparation process thereof | |
| US6903136B2 (en) | Food supplements containing 4-hydroxyisoleucine and creatine | |
| US20030143311A1 (en) | Recovery drink formula and method | |
| CN106072573A (en) | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible | |
| US8124139B2 (en) | Compound preparation for quickly reducing oxidative stress and preparation of the same | |
| CN112772813A (en) | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN102845795A (en) | Functional health-care beverage | |
| US20030104107A1 (en) | Energy drink formula and method | |
| CN114403333A (en) | Effervescent tablet for preventing heatstroke and resisting fatigue and preparation method thereof | |
| CN109007520A (en) | A kind of probiotics plant effervescence tablet and preparation method thereof | |
| CN109043105A (en) | The cordyceps sinensis sea cucumber peptide pressed candy of kidney-tonifying sperm-generating | |
| CN113397176A (en) | Anti-aging composition and preparation method thereof | |
| EP1633377B1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
| CN112618608A (en) | Composition with function of dispelling effects of alcohol and preparation method and application thereof | |
| CN107325163B (en) | Astragalus seed protein and application thereof in anti-sports fatigue functional food | |
| CN1628561A (en) | Combination for releasing lassitude and its preparation method and uses | |
| CN107439866A (en) | Matrimony vine chickpea plant nutrients beverage and its preparation technology | |
| CN103584244A (en) | Preparation method of heat clearing and lung moistening beverage | |
| CN111493314A (en) | Food material nutrient with bioactive substances and solid beverage | |
| CN105079391A (en) | Effervescent tablets for preventing oral ulcer and preparation method therefor | |
| KR20200107809A (en) | Vitamin complex formula coated with xylitol and or Enzymatically Modified Stevia | |
| KR20120119686A (en) | A functional beverage composition comprising l-arginine, vitamin c, vitamin b complex, vitamin a, vitamin e and potassium iodide as main ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |